Heptares to Present at BIO-Europe 2012
WELWYN GARDEN CITY, England and BOSTON, November 8, 2012 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, announces that its Chief Executive Officer, Malcolm Weir, will present the Company at BIO-Europe 2012, the international partnering conference, which takes place at the CCH Congress Center, Hamburg, Germany (12-14 November 2012).
Dr Weir's presentation will be at 2:15pm (CET)on Tuesday 13 November in Room B1, Level 1.
About Heptares Therapeutics
Heptares discovers and develops new medicines targeting GPCRs (Gprotein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.
Heptares is pioneering the application of structure-based drug design to the GPCR super-family of targets and is focused on creating molecules that modulate high-value, yet historically undruggable or challenging, GPCRs. Our platform incorporates proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time.
Using this approach, we have generated a broad pipeline of drug candidates for the treatment of serious disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, chronic insomnia, addiction disorders, migraine and diabetes. For more information about Heptares, please visit http://www.heptares.com.
SOURCE Heptares Therapeutics
More by this Source
Heptares to Present at Upcoming Biotech Industry Conferences
06 Jun, 2013, 09:00 BST
Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
24 May, 2013, 08:00 BST
Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda
29 Apr, 2013, 09:00 BST
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos and customised feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Until you hear the full story, why would you invest?
Making sound investment decisions can be difficult. You can study the figures and read the analyst recommendations, but how do you really know the story behind company strategy? How can you get answers to your questions?
The Private Investor Network helps you to reach an informed decision on the stocks you pick. Interactive presentations from UK listed companies give you the kind of access previously enjoyed only by the big fund managers. And with keynote speeches from industry experts, downloadable content and an investor lounge where you can swap tips with your peers, you can invest with confidence.
For more information, and to register for FREE, visit us at www.privateinvestornetwork.co.uk
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Start today.
Contact PR Newswire
Send us an email at MarketingUK@prnewswire.co.uk or call us at +44 (0)20 7454 5382
Become a PR Newswire client
Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382